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Esophageal cancer is the eighth most common cancer worldwide, and especially in some areas of China is the
fourth most common cause of death and is of squamous cell carcinoma (SCC) histology in >90% of cases. Surgery
alone was the mainstay of therapeutic intervention in the past, but high rates of local and systemic failure have
prompted investigation into multidisciplinary management. In this review, we discuss the key issues raised by the
recent availability of esophageal SCC treatment with the addition of chemotherapy, radiotherapy, and
chemoradiotherapy to the surgical management of resectable disease and discuss how clinical trials and
meta-analysis inform current clinical practice. None of the randomized trials that compared neoadjuvant
radiotherapy or chemotherapy with surgery alone in esophageal SCC has demonstrated an increase in overall
survival in those patients treated with neoadjuvant radiotherapy or chemotherapy. Neoadjuvant chemoradiotherapy
has been accepted recently for esophageal cancer because such a regimen offers great opportunity for margin
negative resection, improved loco-regional control and increased survival. The majority of the available evidence
currently reveals that only selected locally advanced esophageal SCC are more likely to benefit from the adjuvant
therapy. The focus of future trials should be on identification of the optimum regimen and should aim to minimize
treatment toxicities and effect on quality of life, as well as attempt to identify and select those patients most likely
to benefit from specific treatment options.
Keywords: Esophageal cancer, Squamous cell carcinoma, Neoadjuvant therapy, Adjuvant therapy, Chemotherapy,
Radiotherapy, ChemoradiotherapyReview
Introduction
Esophageal cancer is the most rapidly increasing tumor
type in the world [1,2]. Globally, esophageal cancer is
the eighth most common malignancy and sixth most
fatal disease, with approximately 460,000 new diagnoses
and > 380,000 deaths annually [3]. More than one-half of
new cases in western countries have adenocarcinoma
(AC) of the lower esophagus or gastroesophageal junc-
tion; and > 90% patients in eastern Asian countries have
squamous cell carcinoma (SCC) [3,4].* Correspondence: maowmzj1218@163.com
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reproduction in any medium, provided the orDespite improvements in surgical and radiotherapy
(RT) techniques and refinements of chemotherapeutic
regimens, long-term survival, even from localized
esophageal cancer, remains poor. Surgery alone was the
mainstay of therapeutic intervention in the past, but
high rates of local and systemic failure have prompted
investigation into the multidisciplinary management.
Treatment paradigms differ between western and Asian
countries, but the unifying theme that has emerged in
the past decade implies that surgery alone can no longer
be considered the standard of care. In attempts to im-
prove the survival rate, the multidisciplinary manage-
ment involved various combinations and sequences of
all modalities including surgery, RT, chemotherapy (CT),
and chemoradiotherapy (CRT).
The prognosis was different slightly between histo-
logical subtypes. Prior studies have shown that, inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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geal SCC have worse prognosis [5-7]. This difference is
probably due to a different pattern of lymphatic spread
and a greater tendency for the disease to spread locally
[8,9], but more importantly due to the location of the
primary tumor. SCC is usually a proximal lesion, with
75% of these cancers found to have contact with the tra-
cheobronchial tree, while 94% of AC are below the tra-
cheal bifurcation [10].
Neoadjuvant CRT is currently the standard of care for
esophageal AC in many western countries. However, the
optimal treatment strategy for resectable esophageal SSC
is still a controversial topic. In this review, we discuss
the key issues raised by the recent availability for
esophageal SCC treatment with the addition of RT, CT,
and CRT to the surgical management of resectable dis-
ease, and discuss how clinical trials and meta-analysis in-
form current clinical practice.
Neoadjuvant treatments
Neoadjuvant radiotherapy
There have been five phase III randomized trials com-
paring neoadjuvant RT with surgery alone [11-15] in
esophageal SCC (Table 1) and none has demonstrated
an increase in resectability or overall survival (OS) in
those treated with neoadjuvant RT. Although Nygaard
and colleagues reported a 3-year OS benefit, this was
only after pooling patients who had received neoadju-
vant RT with those who had also received neoadjuvant
CRT, as there was no significant difference in survival
found otherwise [14]. Meta-analysis of the five above
mentioned randomized trials only proved a nonstatisti-
cally significant trend (hazard ratio (HR): 0.91, 95% CI:
0.80 to 1.04) in favor of neoadjuvant RT [16].
A recent meta-analysis of trials including data from
1,033 patients, 33% of whom presented SCC, revealed
significantly improved median OS (27 months vs. 18Table 1 Randomized controlled trials of neoadjuvant radioth
carcinoma
Study Histology SCC (%) Treatm
Launois and colleagues [11] SCC 100 NART 4
Surgery
Gignoux and colleagues [12] SCC 100 NART 3
Surgery
Arnott and colleagues [13] AC/SCC 36 NART 2
Surgery
Nygaard and colleagues [14] SCC 100 NART 3
Surgery
Wang and colleagues [15] SCC 100 NART 4
Surgery
aThree-year overall survival (OS). AC adenocarcinoma, MS median survival, NART neomonths, P < 0.0001) and cause-specific survival (35
months vs. 21 months, P < 0.0001) with neoadjuvant RT.
These results support the use of neoadjuvant RT for
patients with esophageal cancer, but patients with SCC
were not analyzed separately [17]. Given the lack of
demonstrated significant benefits of neoadjuvant RT in
SCC patients, a preoperative neoadjuvant radiation treat-
ment strategy is currently not recommended in the SCC
population.
Neoadjuvant chemotherapy
The theoretical advantages of adding CT to the treat-
ment of esophageal cancer are potential tumor down-
staging prior to surgery, as well as targeting micrometa-
static disease and thus decreasing the risk of distant
spread. Potential drawbacks include morbidity and
mortality associated with CT toxicity, selection of
drug-resistant clones, and delay in definitive surgical
management.
Early randomized trials using cisplatin, fluorouracil
(5-FU), bleomycin, vindesine and their combinations
were conducted in patients with SCC of the esophagus
[14,18-21] (Table 2). However, these trials were under-
powered to detect any difference in outcome with the
addition of CT to surgery. Three-year OS rates ranged
from 3 to 43%, despite the use of very similar CT regi-
mens. Two large randomized studies that evaluated
neoadjuvant CT with cisplatin and 5-FU for operable
esophageal AC or SCC had contrasting results. The
smaller Radiation Therapy Oncology Group trial 8911
(US Inter group 113) study reported no survival benefit,
with a median survival of 14.9 months in patients trea-
ted with CT compared with 16.1 months in those re-
ceiving surgery alone (P= 0.53) [22]. Only 31% of
patients in the larger multi-institutional Medical Re-
search Council OE02 study had SCC, reflecting the in-
creasing relative incidence of esophageal AC in the UK.erapy versus surgery alone for esophageal squamous cell
ent n MS (months) 5-year OS (%) P value
0 Gy 77 10 10 NS
57 12 12
3 Gy 106 11 11 NS
102 11 10
0 Gy 90 8 9 NS
86 8 17
5 Gy 48 21a NS
41 9a
0 Gy 104 35 NS
102 30
adjuvant radiotherapy, NS not significant, SCC squamous cell carcinoma.
Table 2 Randomized controlled trials of neoadjuvant chemotherapy versus surgery alone for esophageal squamous
cell carcinoma
Study Histology SCC (%) Treatment n MS (months) 3-year OS (%) P value
Schlag [18] SCC 100 CF 22 7 NS
Surgery 24 6
Nygaard and colleagues [14] SCC 100 BC 44 7 3 NS
Surgery 41 7 9
Maipang and colleagues [19] SCC 100 BVC 24 17 31 NS
Surgery 22 17 36
Law and colleagues [20] SCC 100 CF 74 17 40 NS
Surgery 73 13 13
Ancona and colleagues [21] SCC 100 CF 47 25 34a NS
Surgery 47 24 22a
Kelsen and colleagues [22] AC/SCC 54 CF 213 15 19a NS
Surgery 227 16 20a
Allum and colleagues [23] AC/SCC 31 CF 400 17 43 <0.01
Surgery 402 13 34
aFive-year overall survival (OS). AC adenocarcinoma, BC bleomycin + cisplatin, BVC bleomycin + vindesine + cisplatin, CF cisplatin + fluorouracil, MS median survival,
NS not significant, SCC squamous cell carcinoma.
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(HR: 0.84, 95% CI: 0.72 to 0.98; P= 0.03) with the
addition of CT to surgery [23]. The discrepancy be-
tween the results of the Radiation Therapy Oncology
Group trial 8911 [22] and OE02 [23] studies is due to
the larger proportion of patients with SCC in the
former trial who do not appear to significantly benefit
from this strategy.
In 2008 a Japan Clinical Oncology Group study (JCOG
9907) comparing adjuvant and neoadjuvant CT was
reported, and those results showed that neoadjuvant CT
induced down-staging and R0 reduction and improved
OS without additional serious adverse events [24]. How-
ever, the efficacy of neoadjuvant CT was not compared
with surgery alone in this randomized trial. Prior to the
JCOG 9907 study, the authors had compared adjuvant
CT and surgery alone in the JCOG 9204 study. They
found that the addition of adjuvant CT improved the
disease-free survival rate (from 45 to 55%; P= 0.037) and
the pN1 subgroup 5-year OS (52% vs. 38%, P= 0.041);
however, there was no significant difference in the
5-year OS of the entire cohort (61% with CT vs. 52%
with observation; P= 0.13) [25]. From these data, JCOG
9907 implied that neoadjuvant CT was more beneficial
than surgery alone. Up to now, however, none of the
randomized trials that compared neoadjuvant CT with
surgery alone in esophageal SCC has demonstrated an
increase in OS in those patients treated with neoadju-
vant CT.
In an updated meta-analysis by Sjoquist and colleagues
of nine randomized trials comparing neoadjuvant CT
with surgery alone, in all histological subtypes an HR of0.87 was reported (95% CI: 0.79 to 0.96; P= 0.05) [26].
There was no significant benefit for patients with SCC
(HR: 0.92, 95% CI: 0.81 to 1.04; P= 0.18).
Neoadjuvant chemoradiotherapy
CT combined with RT was initially evaluated as a defini-
tive treatment for patients identified as unable to
proceed with surgery [27]. In combination, CT not only
complements but increases the effect of RT in a process
known as radiation sensitization, as well as complement-
ing synergistic DNA damage, cell cycle synchronization,
and inhibition of repair pathways [28]. In addition to in-
creasing the efficacy of RT and thus controlling local
tumor growth, CT theoretically also offers the ability to
eradicate micrometastatic disease and decrease the risk
of distant recurrence [29].
Several trials have investigated neoadjuvant concurrent
CRT in esophageal SCC compared with surgery alone
[30-36] (Table 3). The results of a phase III randomized
controlled study (FFCD 9901) showed that neoadjuvant
CRT with cisplatin and 5-FU did not improve OS but
enhanced the postoperative mortality rate for patients
with localized stage I or stage II esophageal cancer com-
pared with surgery alone [31]. Another two studies
reported no survival benefit with the addition of CRT
with cisplatin and 5-FU regimens [32,33]. A larger study
that randomized 256 patients with either AC or SCC to
receive concurrent CRT or surgery alone reported no
difference in OS between the two arms. However, a sub-
group analysis demonstrated a significant improvement
in progression-free survival (HR: 0.47, 95% CI: 0.25 to
0.86), although not in OS for the smaller subgroup of
Table 3 Randomized controlled trials of neoadjuvant chemoradiotherapy versus surgery alone for esophageal
squamous cell carcinoma
Study Histology SCC (%) Treatment n MS (months) 5-year OS (%) P value
Bosset and colleagues [30] SCC 100 C+ 37 Gy 143 19 7 NS
Surgery 139 19 9
Lee and colleagues [32] SCC 100 CF + 45 Gy 51 28 49a NS
Surgery 50 27 41a
Burmeister and colleagues [34] AC/SCC 35 CF + 35 Gy 128 22 17 NS
Surgery 128 19 13
Natsugoe and colleagues [33] SCC 100 CF + 40 Gy 22 57 0.58
Surgery 23 41
Tepper and colleagues [35] AC/SCC 25 CF + 50.4 Gy 30 54 39 <0.01
Surgery 26 21 16
Mariette and colleagues [31] AC/SCC 66 CF + 45 Gy 97 32 49a 0.68
Surgery 98 44 55a
Gaast and colleagues [36] AC/SCC 24 PC+ 41.4 Gy 175 49 59a 0.011
Surgery 188 26 48a
aThree-year overall survival (OS). AC adenocarcinoma, C cisplatin, CF cisplatin + fluorouracil, MS median survival, NS not significant, PC paclitaxel + carboplatin, SCC
squamous cell carcinoma.
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Group B 9781 trial of neoadjuvant cisplatin and 5-FU in
weeks 1 and 5 with RT (50.4 Gy in 28 fractions) com-
pared with surgery alone closed to accrual prematurely
having recruited only 56 of the planned 475 patients
with resectable SCC or AC, owing to slow recruitment.
Despite the limited sample size, 5-year OS was signifi-
cantly improved from 16 to 39% in the trimodality arm
and the pathological complete response rate was 40%
[35]. Results from a recent multicenter phase III rando-
mized trial (CROSS study) showed that neoadjuvant
CRT with carboplatin and paclitaxel improved OS com-
pared with surgery alone in patients with resectable (T2-3,
N0-1, M0) esophageal or gastroesophageal junction can-
cers. The reported rate of R0 resection was higher in the
CRT arm compared with the surgery alone arm (92% vs.
65%). The OS was significantly better for patients treated
with CRT. Median survival was 49 months in the CRT
arm compared with 26 months in the surgery alone arm.
The 1-year, 2-year and 3-year survival rates were 82%,
67% and 59% respectively in the CRT arm and 70%, 52%
and 48% respectively in the surgery-alone arm [36].
The updated meta-analysis of 12 randomized com-
pared neoadjuvant CRT with surgery alone. The HR for
all-cause mortality for neoadjuvant CRT was 0.78 (95%
CI: 0.70 to 0.88; P < 0.0001), the HR for SCC only was
0.80 (95% CI: 0.68 to 0.93; P= 0.004) and the HR for AC
only was 0.75 (95% CI: 0.59 to 0.95; P= 0.02) [26]. Al-
though this meta-analysis favors the neoadjuvant CRT
approach for patients with SCC, this approach is also
associated with significant treatment-related mortality
and morbidity in this often malnourished population,who frequently have multiple smoking-related co-mor-
bidities. The effectiveness of CRT with high pathological
complete response rates prompted investigation of rad-
ical CRT as a definitive treatment modality to avoid sur-
gical morbidity and mortality. The meta-analysis
performed by Kranzfelder and colleagues, however,
demonstrated that none of the randomized controlled
trials was reporting an outcome of higher survival benefit
after definitive CRT than neoadjuvant treatment followed
by surgery, but treatment-related mortality rates were
lower (HR 7.60; P= 0.007) than with neoadjuvant treat-
ment followed by surgery or surgery alone [37]. On the
other hand, Akutsu and colleagues investigated the clin-
ical and pathologic results of neoadjuvant CRT in 78
patients that underwent an esophagectomy after neoad-
juvant CRT. They found that the clinical evaluation for
CRT does not reflect the pathologic effectiveness; even if
clinical complete response was achieved, viable cancer
cells were still present at the primary site in the majority
of the population [38].
Adjuvant treatments
Adjuvant radiotherapy
Adjuvant RT has also been evaluated in five small studies
[39-43] (Table 4). A meta-analysis of these trials demon-
strated no significant improvement in 5-year OS with the
addition of RT to complete surgical resection [44].
Ténière and colleagues evaluated 221 patients with
SCC of the middle to lower third of the esophagus who
were randomized to adjuvant RT at a dose of 45 to 55
Gy versus observation [40]. They found that although
local control improved from 15 to 30%, there was no
Table 4 Randomized controlled trials of adjuvant radiotherapy versus surgery alone for esophageal squamous cell
carcinoma
Studies Histology SCC (%) Treatment n MS (months) 5-year OS (%) P value
Kunath and Fischer [39] SCC 100 ART 50 to 55 Gy 23 9 NS
Surgery 21 6
Ténière and colleagues [40] SCC 100 ART 45 to 55 Gy 102 18 19 NS
Surgery 119 18 19
Fok and colleagues [41] SCC 100 ART 43 to 53 Gy 42 11 10 NS
Surgery 39 22 16
Zieren and colleagues [42] SCC 100 ART 56 Gy 33 23a NS
Surgery 35 22a
Xiao and colleagues [43] SCC 100 ART 50 to 60 Gy 220 41 NS
Surgery 275 32
aThree-year overall survival (OS). ART adjuvant radiotherapy, MS median survival, NS, not significant, SCC squamous cell carcinoma.
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and colleagues also randomized 130 patients with
esophageal carcinoma (SCC or AC) to observation ver-
sus adjuvant RT at a dose of 49.5 Gy in 3.5 Gy fractions
[41]. They found that although local failure was reduced
from 31 to 15% (P= 0.06), the median OS was actually
worse in the adjuvant RT arm (8.7 months vs. 15.2
months, P= 0.02). This trial has been criticized, however,
for the high dose per fraction that may have led to
increased mortality in the radiation-containing arm. Zieren
and colleagues randomized 68 patients with SCC to either
adjuvant RT or surgery alone and found that adjuvant RT
significantly increased the fibrotic stricture rate and did
not improve OS or disease-free survival [42]. Malthaner
and colleagues [44] performed a meta-analysis of 995
patients from five randomized trials of adjuvant RT versus
observation. They found that there was no OS benefit with
the addition of adjuvant RT, with a risk ratio for death at 1
year of 1.23 (95% CI: 0.95 to 1.59, P=0.11). Suggestions
therefore indicate there are few data to suggest that adju-
vant RT offers any survival benefit. However, both Ténière
and colleagues [40] and Zieren and colleagues [42]
included patients with positive celiac nodes (stage M1a).
These patients represent a cohort at much higher risk forTable 5 Randomized controlled trials of adjuvant chemothera
carcinoma
Study Histology SCC (%) Treatm
Pouliquen and colleagues [46] SCC 100 CF
Surger
Ando and colleagues [47] SCC 100 CV
Surger
Ando and colleagues [25] SCC 100 CF
Surger
CF cisplatin + fluorouracil, CV cisplatin + vindesine, MS median survival, NS not signifdistant failure and therefore are less likely to benefit from
adjuvant RT. Finally, the meta-analysis included the above
flawed trials.
Xiao and colleagues [43] randomized 495 patients with
esophageal SCC to radical resection alone versus adju-
vant RT at a total dose of 50 to 60 Gy in 2 Gy fractions.
Once again, there was no survival benefit for the entire
cohort with the addition of adjuvant RT, with a 5-year
OS of 31.7% for surgery alone versus 41.3% for adjuvant
RT (P= 0.447). When stratifying based on stage, how-
ever, there was a significant survival benefit with adju-
vant RT for stage III patients, with an improvement in
5-year OS from 13.1 to 35.1%, (P= 0.003) but not for
stage II patients. Similar to the findings mentioned
above, Chen and colleagues retrospectively evaluated
patients with thoracic esophageal SCC [45]. They
reported that adjuvant RT was associated with a statisti-
cally significant improvement in survival, but only in
those patients with three or more involved lymph nodes;
no such association was found in patients with one or
two involved lymph nodes.
In summary, the majority of the available evidence
currently reveals that only selected locally advanced
esophageal SCC are likely to benefit from adjuvant RT.py versus surgery alone for esophageal squamous cell







icant, OS overall survival, SCC squamous cell carcinoma.
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Adjuvant CT with cisplatin-based regimens compared
with surgery alone has been examined in three separate
phase III trials [25,46,47] (Table 5). None of these trials
reported a statistically significant difference in OS, al-
though Ando and colleagues reported a 5-year OS ad-
vantage (52% vs. 38%, P= 0.041) in the pN1 subgroup
patients [25].
Two JCOG trials studied adjuvant CT for resected SCC
of the esophagus. In the first study, 205 patients with
resected SCC of the esophagus were randomized to re-
ceive two cycles of adjuvant CT with cisplatin 70 mg/m2
(day 1) and vindesine 3 mg/m2 (day 1) or observation
only. No significant benefit in survival was detected from
the addition of this adjuvant CT regimen (5-year OS:
48.1% vs. 44.9% with observation; P= 0.55) [47]. The
follow-up JCOG 9402 study randomized 242 patients with
resected SCC of the esophagus to two cycles of cisplatin
80 mg/m2 (day 1) and 5-FU 800 mg/m2 /day (days 1 to 5)
or observation. The addition of this adjuvant CT regimen
improved the disease-free survival rate (from 45 to 55%;
P=0.037) and the pN1 subgroup 5-year OS (52% vs. 38%,
P=0.041); however, there was no significant difference in
the 5-year OS (61% with CT vs. 52% with observation;
P=0.13) [25].
Adjuvant chemoradiotherapy
The efficacy of adjuvant CRT has not been compared
with surgery alone in a randomized trial in patients with
esophageal SSC. The National Comprehensive Cancer
Network does recommend postoperative adjuvant CRT
for stages II and III esophageal AC. This recommenda-
tion is based on a randomized phase III trial by Macdo-
nald and colleagues that found adjuvant CRT improved
3-year OS from 41 to 50% in AC of the stomach and
gastroesophageal junction [48]. A small randomized trial
of 45 patients compared adjuvant CT using cisplatin 50
mg/m2 (days 1 and 15) and 5-FU 300 mg/m2 /day (for 5
weeks) with adjuvant CRT after R0 resection of esophageal
SCC. No significant difference in 5-year OS was demon-
strated (38% CT vs. 50% CRT; P=0.97), but the study was
limited by the small sample size [49].
Discussion
None of the randomized trials that compared neoadju-
vant RT or CT with surgery alone in esophageal SCC
has demonstrated an increase in OS in those patients
treated with neoadjuvant RT or CT. Neoadjuvant CRT
has been accepted recently for esophageal cancer be-
cause such a regimen increases the rates of R0 resection
and local tumor control. The updated meta-analysis also
favors the neoadjuvant CRT approach for patients with
SCC [26]. Another recent meta-analysis demonstrated
that the esophageal SCC in Europe and in the USAbenefited from neoadjuvant CRT; however, patients in
Asia did not benefit [50]. Ethnic difference makes it ne-
cessary to re-evaluate the role of neoadjuvant CRT in
patients with SCC in Asia.
Phase III trials have compared adjuvant RT with sur-
gery alone without demonstrating any OS benefit, except
in stage III patients (35.1% vs. 13.1%, P= 0.003) [44].
The phase II nonrandomized trial for patients with
node-positive (T3 or T4) tumors indicated that the out-
comes of adjuvant CRT are better than the historical
outcomes with surgery alone [49]. The retrospective
study indicated that adjuvant RT was associated with a
statistically significant improvement in survival, but only
in those patients with three or more involved lymph
nodes [45]. The addition of adjuvant CT only improved
the pN1 subgroup 5-year OS [25]. The majority of the
available evidence therefore currently reveals that only
selected locally advanced esophageal SCC are more
likely to benefit from the adjuvant therapy. The National
Comprehensive Cancer Network recommends upfront
surgery only for select patients with clinical T1 disease.
For all other disease stages, CRT, preoperative CRT, or
preoperative CT is recommended [51]. The current evi-
dence reveals that primary surgery followed by adjuvant
therapy should be used cautiously in clinical practice
until appropriately powered randomized trials confirm
the adjuvant treatment results of this disease.
Although both neoadjuvant CRT and adjuvant CRT
have emerged as more useful options for the treatment
of resectable esophageal SCC, it is hard to identify which
is better based on current knowledge in the lack of
head-to-head randomized controlled trials. Designing
proper multidisciplinary studies that include use of novel
systemic chemotherapies, optimizing radiation techni-
ques, and identifying patient and tumor-specific markers
predictive for response and/or toxicity remains an ur-
gent need for the future. The approach is currently being
explored in China by investigators of the ZTOG1201
trial, a multicenter phase II trial of neoadjuvant and ad-
juvant CRT in locally advanced esophageal cancer
(NCT01463501).
Future trials should investigate further ways to im-
prove upon current loco-regional control and survival.
Opportunities for development include use of novel che-
motherapies. Docetaxel was recently reported as a
powerful anticancer agent for esophageal cancer in nu-
merous trials. Cisplatin plus docetaxel, with or without
5-FU, has demonstrated activity in patients with locally
advanced EGI or metastatic esophageal SCC [52-54]. A
small-sample retrospective study has also showed that
preoperative combined CT with docetaxel plus cisplatin
and 5-FU followed by surgery provided a high response
rate and a favorable survival benefit in patients with re-
sectable esophageal SCC [55]. In the docetaxel plus
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92.3%; 30.8% patients had complete response, 61.5% par-
tial response, 7.7% stable disease, and 0 progressive
disease. To validate the clinical significance of this
novel CT regimen, large-sample randomized trials are
essential.
Conclusion
None of the randomized trials that compared neoadju-
vant RT or CT with surgery alone in esophageal SCC
has demonstrated an increase in OS in those patients
treated with neoadjuvant RT or CT. Neoadjuvant CRT
has been accepted recently for esophageal cancer be-
cause such a regimen offers great opportunity for margin
negative resection, improved loco-regional control and
increased survival, and should be an optional treatment
paradigm. The majority of the available evidence cur-
rently reveals that only selected locally advanced esopha-
geal SCC are more likely to benefit from the adjuvant
therapy. The focus of future trials should be on identifi-
cation of the optimum regimen and should aim to
minimize treatment toxicities and effect on quality of
life, as well as attempt to identify and select those
patients most likely to benefit from specific treatment
options.
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